Skip to content

Viridian Therapeutics, Inc. VRDN Change in Other Assets

Change in Other Assets at other companies

Amgen logo
AmgenAMGN
-$8M-104%
Immunovant, Inc. logo
Immunovant, Inc.IMVT
-$1.3M-767%
Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
-$382K+92.4%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
-$949K-116%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
-$7.84M-30.8%
Vera Therapeutics logo
Vera TherapeuticsVERA
$5.14M-12.5%

Other financials

Income statement

See full
Revenue$141.0K+95.8%
Operating income-$116.2M-23.8%
Net income-$104.9M-20.7%
EPS (diluted)-$1.15-5.5%

Balance sheet

See full
Cash & equivalents$176.3M+51.7%
Total debt$36.8M+59.4%
Total equity$636.0M+5.2%
Total assets$789.0M+19.4%

Cash flow

See full
Operating cash flow-$119.7M-29.1%
CapEx$23.0K-73.3%
Free cash flow-$119.7M-29.0%

Valuation

See full
Market cap$1.91B+82.0%
Enterprise value$1.77B+85.0%
P/S26.9×-3,445×

Profitability

See full
Gross margin36.3%
Operating margin-543.9%-271pp
Net margin-508.5%-254pp
FCF margin-428.4%-214pp

Returns & leverage

See full
Return on equity-58.1%+7.9pp
Debt / equity0.1×0.0×
Current ratio15.1×-4.3×

Where this comes from

Reported directly by Viridian Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.

The official record: Viridian Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Viridian Therapeutics, Inc.'s change in other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Viridian Therapeutics, Inc.'s change in other assets?
Viridian Therapeutics, Inc. (VRDN) reported change in other assets of $2.33M in Q1 2026.
How has Viridian Therapeutics, Inc.'s change in other assets changed year-over-year?
Viridian Therapeutics, Inc.'s change in other assets increased by 918.9% year-over-year, from -$285K to $2.33M.
What does change in other assets mean?
Change in miscellaneous assets affecting operating cash flow.